We also used @Leafly data to match sample strain names with their common, commercial Indica/Hybrid/Sativa designation, and assess the level of consumer popularity associated with each strain name.
So... here is a brief summary of what we saw.
5/
Cannabinoid diversity.
>95% of commercial #cannabis in the US is THC-dominant.
Almost all the variation in cannabinoid content is explained by variation in total THC, CBD, and CBG levels, with THC explaining the bulk.
6/
Based on biochem of cannabinoid production, there are constraints on cannabinoid ratios you will see.
This is why you see three distinct THC:CBD chemotypes and correlations between THC/CBD/CBG.
So, we see what you'd expect. Not much cannabinoid diversity beyond THC levels.
7/
Terpenes.
First, we looked at which terpenes were most common. Across states, we see a similar set of terpenes that are more abundant than others.
For example, myrcene, caryophyllene and limonene are the most abundant.
8/
Looked for certain terpene correlations were reliably present across states, which we also expect from the biology.
Example: caryophyllene and humulene have a strong correlation due to the biochem of how they are produced.
Saw this in each state, mostly as a sanity check.
9/
Next, looked at all terpenes consistently measured in each state & how they correlate with each other.
Lots of terpenes correlate with certain other terpenes, i.e. there are "entourages" of terpenes you tend to find in different #cannabis samples.
10/
Again, what we expected to see based on past work. We saw that these patterns are present across US states.
Network diagram below is a more compact picture of which terpenes tend to co-occur most often. Thicker lines = stronger correlation between terpenes.
11/
Most of US #cannabis is THC-dominant, not CBD-dominant or Balanced. But are the THC-dominant samples also more diverse in terms of terpene profiles?
A: Yep.
High-CBD flower is less diverse, with a higher % of samples being myrcene-dominant compared to high-THC samples.
12/
So... let's focus on the chemical diversity we see among THC-dominant samples, which represent the bulk of commercial #cannabis.
How well do Indica/Hybrid/Sativa labels map to the chemical diversity we actually see in THC-dominant #cannabis?
13/
Most budtenders will tell you, confidently: Indicas are sedating, Sativas are energizing.
If true, you'd expect to see that "Indica" and "Sativa" samples, *as they are labelled & presented to consumers,* should display, on average, some kind of chemical difference...
14/
We took all the THC-dominant samples where the producer supplied a strain name, matched those to their most common commercial Indica/Hybrid/Sativa designation (using @Leafly), and looked at how well these labels map to the underlying terpene profiles...
15/
If the Indica/Sativa labels mapped to distinct terpene profiles you'd expect to mostly see Indica dots (purple) on one side of the chart, Sativa dots (red) elsewhere, and Hybrid dots (green) in between.
16/
That's NOT what we see... but if you squint, maybe there's a mostly red clump of dots near the top, in the cloud of dots on upper part of graph?
(I'll come back to this).
Basic observation: Indica/Hybrid/Sativa labels do not map to terpene variation very well overall.
17/
You can explain diversity in terpene profiles for THC-dominant #cannabis by just knowing the single most abundant terpene for each sample. That has a lot more explanatory power than Indica/Sativa.
18/
We also used a clustering algorithm to look at the same data. This analysis allows to define in a more unbiased way how many distinct terpene chemotypes we see for commercial #cannabis in the US.
19/
A: About three.
You can lump of split these further, but the three major terpene profiles we see can be described as:
1.) Very high myrcene with pinene
2.) High caryophyllene + limonene
3.) High terpinolene
Note, these are relative levels, not all-or-none differences.
/20
We see the same basic pattern across all six US states. So, it's not like the #cannabis in California is filled with a chemotype you never see in Michigan, or something like that.
The major terpene profiles we see among THC-dominant cannabis show up reliably across states.
/21
We further quantified how well (or poorly) these different approaches to labelling samples capture the underlying chemistry.
Violin chart on the left shows that using "Commercial Category" (Indica/Sativa) to label samples does NOT tell you much about product chemistry.
/22
We used used another visualization technique (UMAP) to represent the terpene profiles of our THC-dominant samples.
Dots are color-coded by which of the three main clustering we defined with our clustering algo. Notice that some clusters have more dots than others.
/23
We can simply average all the profiles in each cluster to see what the relative ratios of major terpenes are for #cannabis samples in each cluster:
/24
What about the strain names? First, we looked at the correlation between how many samples of lab data were attached to each strain name and how often the corresponding pages on @Leafly are viewed.
i.e. does consumer popularity correlate w/ number of products tested?
A: Yes
/25
Next, took 10 most popular strain names, looked at similarity of terpene profiles across each producer that had several or more samples w/ that strain name.
Not going to fully unpack, but matrix shows how similar products are across producers across these strain names.
/26
So, we can measure how similar the profiles are for each product w/ a given strain name, across producers.
In other words, we might have 50 producers with "Original Glue" #cannabis samples. For each producer, we compare their Original Glue product to the other producers'.
/27
That gives us a set of numbers, each one telling us how similar two Original Glue products is. For each strain name we have a range of such similarity numbers (and an average for that strain name).
We do this for each strain name we have a good amount of data for:
/28
Key is where each blob is compared to dashed line, which is the number you get if you randomly shuffle all strain names across all products.
So: how consistent is each strain name, product-to-product, compared to what you'd see if everyone choose strain names randomly?
/29
Many strain names are *more* similar than you'd expect from the random shuffle, a couple are *less* similar, and some show no more product-to-product similarity than you'd expect if people named their products at random.
/30
This result may surprise some. I think many people expect that the strain names are totally haphazardly applied, and contain absolutely no information about the underlying product chemistry.
That does not appear to be true, at least for certain popular strain names.
/31
Important to recognize that even the strain names that display statistically significant product-to-product similarity, they still tend to display a quite a wide range.
/32
If you randomly pick up two distinct #cannabis flower products that share the same strain name, the odds that they have the same basic chemotype depends heavily on which strain name they share.
/33
Let's look at two concrete examples: Purple Punch displays relatively high product-to-product similarity, while Tangie does not.
Most (but not all) Purple Punch products fall into our "high caryophyllene-limonene" cluster, while Tangie is all over the place.
/34
Looking at the same comparison in a different way, we can highlight products attached to either Purple Punch or Tangie in the context of our UMAP visualization.
This is showing you where these products fall within the full landscape of terpene profiles we observe.
/35
Purple Punch products (black triangles) are in the same basic neighborhood (similar chemotype).
To me, this is remarkable, b/c we're talking about products made by separate producers, who are often in separate US states.
In contrast, Tangie products are all over the map.
/36
Ok, let's go back to the Indica/Sativa thing. Previously we showed that Indica/Sativa labels do NOT do well at explaining overall variation in terpene profiles.
But... is there any over-representation of Indica vs. Sativa-associated strain names in *any* of the clusters?
/37
A: There is, in one place.
Our "high terpinolene" cluster contains an overrepresentation of samples with strain names associated with "Sativa" designations.
/38
This is pulling out the potential pattern we had to squint to see earlier.
Going on a slight tangent, this pattern reminds me of something @trichomics and colleagues have seen before, analyzing genomic data.
Anyways, what about strain names? Are any overrepresented in our clusters?
A: Yes
/40
Ok, this is an obnoxiously long thread, so I will leave it there. We think these results help move our chemotaxonmic understanding of commercial #cannabis forward, and can inform the design of both animal and human studies.
/41
If we want to test common claims about distinct psychoactive or medicinal effects common from different types of #cannabis, then we should design experiments that use chemical ratios similar to those observed in the cannabis people are using under 'ecological' conditions.
/42
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#ScienceBreakdown: A group of scientists (@DEOlsonLab) created an ibogaine analog lacking nasty properties of ibogaine but retaining desirable ones. It is also claimed to be non-hallucinogenic.
Ibogaine is an alkaloid found in iboga, a shrub from West Africa. It's a dissociative psychedelic and can induce intense hallucinations that last for many hours.
Prelim evidence suggests it may help treat addiction, but it can also have serious side-effects.
2/
You obviously don't want a drug to have severe side-effects, and ibogaine has some, including cardiotoxicity (heart damage).
There's also a push in the psychedelic drug space to develop psychedelic analogs that retain therapeutic properties but don't induce hallucinations.
3/
#ScienceBreakdown: Is DMT produced by the pineal gland in the mammalian brain?
I often see this claim on the internet and am surprised how often I'm asked about it. Below, a breakdown of a 2019 study in (mostly) rats looking at this.
For those that don't know, DMT is arguably the most powerful hallucinogen. It's typically smoked/vaporized. Subjective effects are intense but short-acting (minutes). The peak minutes produce a completely transformed experience, utterly alien compared to normal consciousness.
2/
First, some background on the science:
#DMT has been detected in mammalian tissues before. Usually this has been outside the brain, in very small amounts, making it questionable whether it's physiologically relevant or just a metabolic byproduct.
Acute Respiratory Distress Syndrome (ARDS) = deadly condition where lungs get super inflamed b/c immune system responds too strongly. This leads to lots of collateral damage to throughout the body.
Mortality rate in humans = 38.5%. No current drugs exist that help very much.
2/
ARDS can be induced by "super antigens," e.g. bacterial proteins like SEB that cause immune system to go haywire. If you expose mice to SEB, 100% die within ~one week.
Basic question: can death from ARDS be prevented by an immunosuppressive like THC?
Getting questions about recent @Forbes article. Article makes good points + gives good advice, but also makes erroneous claims based on misreading recent #cannabis research. Basic claims of article + breakdown of the new study in this thread. 1/
Many #cannabis consumers buy weed based on THC level, trying to get the most THC for their $. High THC weed sells faster. Article says that buying weed based just on THC is a bad idea. There's more to quality than just THC %. I agree with this, but the article goes further... 2/
The article is making the further claim that THC content is a poor indicator of #cannabis potency, and that weed with higher THC levels will *not* get you more high.
Wait? So if you consume flower with 18% THC, it will get you just as high as a concentrate with 80%?
1/n, Several people asked me about this headline, on a recent preprint claiming that #cannabis extracts high in #CBD have, "the potential of reducing [#coronavirus] infection by 70 to 80 percent.” Quite a claim. Let's briefly look at the study...
2/n, Remember, this a preprint, so hasn't been peer-reviewed and people are rushing to get #COVIDー19 related studies out ASAP. Let's briefly look at what they did and some results. Are the experiments/results compelling, or is this an absurd rush job (place your bets now!) ...
3/n, Basically, what they did was take cultures of human-derived cells (e.g. oral epithelial cells), put #cannabis extracts onto them, and ask if transcript (mRNA) or protein levels of ACE2 were impacted. ACE2 is an important protein #coronavirus uses to infect cells.